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A mix-and-read drop-based in vitro 
two-hybrid method for screening 
high-affinity peptide binders
Naiwen Cui1,*, Huidan Zhang1,2,*, Nils Schneider3,4,*,†, Ye Tao1,5, Haruichi Asahara4, Zhiyi Sun4, 
Yamei Cai6, Stephan A. Koehler1, Tom F. A. de Greef7, Alireza Abbaspourrad1, David A. Weitz1,8 
& Shaorong Chong4
Drop-based microfluidics have recently become a novel tool by providing a stable linkage between 
phenotype and genotype for high throughput screening. However, use of drop-based microfluidics 
for screening high-affinity peptide binders has not been demonstrated due to the lack of a sensitive 
functional assay that can detect single DNA molecules in drops. To address this sensitivity issue, we 
introduced in vitro two-hybrid system (IVT2H) into microfluidic drops and developed a streamlined 
mix-and-read drop-IVT2H method to screen a random DNA library. Drop-IVT2H was based on the 
correlation between the binding affinity of two interacting protein domains and transcriptional 
activation of a fluorescent reporter. A DNA library encoding potential peptide binders was encapsulated 
with IVT2H such that single DNA molecules were distributed in individual drops. We validated drop-
IVT2H by screening a three-random-residue library derived from a high-affinity MDM2 inhibitor PMI. 
The current drop-IVT2H platform is ideally suited for affinity screening of small-to-medium-sized 
libraries (103–106). It can obtain hits within a single day while consuming minimal amounts of reagents. 
Drop-IVT2H simplifies and accelerates the drop-based microfluidics workflow for screening random 
DNA libraries, and represents a novel alternative method for protein engineering and in vitro directed 
protein evolution.
Protein-protein interactions (PPIs) regulate cellular physiology by influencing interactome networks. Between 
40,000 and 200,000 PPIs have been predicted to exist within the human interactome, and their malfunction is one 
of the fundamental causes of human diseases1,2. One promising therapeutic strategy involves the use of peptide 
drugs with high target-specific affinities to regulate certain PPIs3. Compared with protein and small-molecule 
drugs, therapeutic peptides offer the advantages of better cell penetration, less immunogenicity and greater spec-
ificity4,5. More than 60 synthetic therapeutic peptides have recently reached pharmaceutical markets6. For exam-
ple, Degarelix (Firmagon), a gonadotrophin-releasing hormone receptor blocker, has been shown effective for the 
treatment of men with advanced hormone-sensitive prostate cancer7.
Currently, molecular display represents the most widely used high-throughput techniques for screening 
high-affinity peptide binders. Taking the advantage of living cells’ ability to express a DNA library and display the 
protein or peptide products on their surfaces, in vivo display systems utilize phage, bacterium and yeast to estab-
lish a physical link between the binding affinity to a target molecule (phenotype) and the DNA sequence (geno-
type) of the displayed molecule. However, such in vivo systems often suffer from serious drawbacks, such as low 
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transformation efficiency, expression bias, toxicity of fusion proteins and interference of other surface proteins 
during selection8–10. In comparison, cell-free display systems, such as ribosome and mRNA display, contain only 
the essential elements for protein expression and thus provide an in vitro solution to address some of these issues. 
However, cell-free display systems also have their own drawbacks. For instance, in the ribosome display method, 
potential protein or peptide binders are expressed from a DNA library and through ribosomes form a linkage 
with their coding mRNAs11,12. The binders with high affinities towards a target are selected through “biopanning”, 
a series of washing and amplification cycles. Such selection conditions can destabilize the mRNA-binder complex. 
The mRNA display method improves the stability by establishing a covalent linkage between the binder and its 
coding mRNA. Nevertheless, the RNA-binder complexes are inherently unstable which can severely restricts the 
screening conditions13,14. Moreover, the selection of high-affinity binders using biopanning in both ribosome 
and mRNA display methods can be biased by the dissociation kinetics of the binder to the target molecule. A 
recently reported bead display method circumvents some of these drawbacks by displaying binder-DNA conju-
gates on monoclonal beads, which are subsequently screened using flow cytometer15–17. It is unclear whether the 
binding to the target molecule is affected by the attachment of the binder to a large heterogeneous bead surface. 
Drop-based microfluidics has become a novel tool for high throughput screening in recent years. It provides 
a stable linkage between phenotype and genotype by partitioning single cells into picoliter drops and allows 
fluorescence-activated drop sorting (FADS)18,19. However, the use of such drop-based microfluidic method to 
screen high-affinity binders from a random DNA library has never been shown, largely due to the fact that there 
is no functional assay sensitive enough to detect single DNA molecules for protein binding in drops.
Here we combined drop-based microfluidics with our recently developed in vitro two-hybrid system (IVT2H) 
– an in vitro assay for detection of protein-protein interaction20, and demonstrated a simple and cost-effective 
screening platform, which we named “drop-IVT2H”. We encapsulated single DNA molecules of a peptide library 
in picoliter drops with the IVT2H reagents containing plasmids expressing the target protein. Drops were incu-
bated off-chip to allow the expression of both binder and target proteins. The binding of a high-affinity binder 
to the target protein activated the GFP expression in situ, resulting in highly fluorescent drops (bright drops). 
These bright drops were isolated by the FADS device and the high-affinity binders were subsequently identified 
by DNA sequencing. We demonstrate that this mix-and-read drop-IVT2H has allowed successful enrichment of 
high-affinity peptide binders in a p53-MDM2 binding model.
Materials and Methods
IVT2H reagents and DNA constructs. IVT2H reagents are described previously20–22. Briefly, IVT2H con-
tained 144 nM purified E. coli RNA polymerase core enzyme, 1.2 μM purified recombinant E. coli IHF, 0.8 units/μl 
murine RNase inhibitor, the PURExpress® in vitro protein synthesis system (New England Biolabs), 0.2 ng/μl 
(45 pM) plasmid DNA expressing σ 54, 4.4 nM linear reporter DNA expressing GFP and 0.2 ng/μl (60 pM) plas-
mid DNA expressing hybrid fusion protein AD-MDM2, in which the activation domain (AD, residues 1–296) of 
PspF was fused to the full-length human MDM2 protein. The genes for the wild-type p53 peptide (p53p, residues 
17–26: ETFSDLWKLLPE) and the peptide inhibitor (PMI: TSFAEYWNLLSP) were synthesized and fused to the 
N-terminus of the DNA binding domain Cro (DB). The linear DNA constructs expressing p53p-DB, PMI-DB or 
the PMI library-DB were used in drop-based microfluidics experiments.
Construction of the full-length PMI Library. The PMI library was constructed by randomizing the 
hydrophobic triad, FWL of the PMI sequence (underlined: TSFAEYWNLLSP)23,24. The DNA fragments contain-
ing T7 promoter and the randomized PMI sequences were assembled from four overlapping oligonucleotides 
(fw1, fw2, rv1 and rv2). MNN codon (antisense codon, M = A, C and N = A, T, G, C) was introduced in rv2 to 
replace each of FWL residues with 20 amino acids. The primer fw2 and rv2 were modified with 5′ phosphoryla-
tion (Integrated DNA Technologies). Equal molar amounts of the oligonucleotides were annealed in NEB buffer 
3 by gradually cooling the primer mixtures from 95 °C to 23 °C. T4 DNA polymerase and T4 DNA ligase were 
added to perform gap filling in the presence of 200 μM dNTP at 23 °C for 30 min followed by heat inactivation at 
75 °C for 20 min in the presence of 10 mM EDTA. The resulting DNA fragments were fused to the DNA fragments 
containing DB and T7 terminator by overlapping PCR. The scheme for constructing the full-length PMI library is 
shown in Figure S1. The random full-length PMI DNA library should contain 20 × 20 × 20 = 8000 PMI variants. 
The actual frequencies of PMI variants were determined by deep-sequencing analysis (Supplementary Table S2).
Microfluidic Device Fabrication. We fabricated polydimethylsiloxane (PDMS) microfluidic devices using 
standard soft lithographic methods. The microfluidic channel walls were rendered hydrophobic by treating them 
with Aquapel (PPG)25. To fabricate the device for sorting experiments, we filled the designed channels with 
Indalloy 19 (51In, 32.5 Bi, 16.5 Sn; 0.020 inch diameter), a low melting point metal alloy (Indium Corporation). 
We made electrical connections using eight-pin terminal blocks (Phoenix Contact)26. The microfluidic setup and 
design are shown in Supplementary Figure S4.
Drop encapsulation and off-chip incubation. Linear DNA fragments expressing p53p-DB, PMI-DB, 
FSL-DB, FWR-DB (0.5 ng/μl) or the PMI library (1 ng/μl) were freshly diluted and added to the IVT2H reagents 
(25 μl) such that the final concentration of the binder templates was 10.8 fg/μl (8 fM). The solution was kept on 
ice to minimize transcription and translation before encapsulation into drops. A microfluidic device containing a 
flow-focusing junction with a cross section of 15 × 15 μm2 was used to encapsulate this solution into ∼ 3 million 
monodisperse drops with diameter of 24 μm (7.2 picoliter) in HFE-7500 fluorinated oil (3 M), containing 1% 
(w/w) Krytox-PEG diblock co-polymer surfactant (RAN Biotech)27,28. These 24 μm drops formed a cylindrical 
shape after the flow-focusing junction with a cross section of only 15 × 15 μm2. The drops had a larger diameter 
than that of the channel and were squeezed between the walls of the channel.
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Rather than driving the flow using syringe pumps, we applied a house vacuum (− 0.4 PSI) (Model 4172K12, 
McMaster-Carr Supply Company, Elmhurst, IL) at the outlet of the device to suck the reagents that were placed 
directly into the inlets through the microfluidic channels. The applied vacuum was not electrically controlled. 
Rather, the house vacuum was connected to the microfluidic drop maker through a vacuum regulator valve, 
which regulates the vacuum applied to the device. Simply by opening the valve and keeping the vacuum at a 
consistent value, we were able to generate monodispersed drops at a stable frequency. This vacuum-driven setup 
is robust, easy-to-use and low-cost. In addition, there are no initial transients in drop-size and no dead volumes 
of reagents, which are often seen inside the syringe, tubing and device in the pump-driven setup. These benefits 
make the vacuum-driven setup very suitable for encapsulation of a small volume of reagents for expensive bio-
logical assays. A recently published paper has described the detailed application of this setup and its advantages29.
The generated water-in-oil emulsion was collected in a PCR tube directly, covered with mineral oil and incu-
bated at 37 °C for 6 hr. This drop-making procedure is schematically shown in Fig. 1A. The actual image of the 
setup and the microfluidic chip designs are shown in Supplementary Figure S4. The typical drop generation rate 
was about several thousand drops/sec.
FADS and drop collection. To detect and isolate bright drops containing PMI or high-affinity MDM2 bind-
ers, we used FADS as described previously30. The incubated drops were re-injected into a microfluidic sorter at a 
flow rate of 20 μL/h and evenly spaced by HFE-7500 oil with surfactant flowing at a rate of 180 μL/h. During this 
Figure 1. A schematic workflow for screening high-affinity binders using drop-based in vitro two-
hybrid method (drop-IVT2H). (A) Single DNA templates and IVT2H reagents were encapsulated in drops 
on a microfluidic chip by applying vacuum to generate monodisperse drops. The binder DNA template was 
distributed as single copy in drops based on Poisson statistics. Each drop contained multiple copies of the 
reporter and target DNA templates. Drops were then collected for off-chip incubation. Inset, the IVT2H 
reaction during off-chip incubation. PMI-DB and AD-MDM2 were expressed from the binder and target 
templates, respectively. PMI-DB bound the upstream activation sequence (UAS) on the reporter DNA. The 
interaction of PMI and MDM2 recruited AD to the promoter-bound RNA polymerase (RNAP) and activated 
the expression of the reporter gene, producing the fluorescent GFP. (B) After incubation, drops were re-injected 
into a fluorescence-activated drop sorting device (FADS). Co-flowing spacing oil ensured equal separation of 
drops. Both bright and dark drops were isolated and collected in separate tubes for RT-PCR followed by Sanger 
or deep sequencing.
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drop re-injection phase, we used two micro-liter constant-flow-rate syringe pumps and set the flow rates of the 
pumps at 20 μL/h and 180 μL/h to push the drops and spacing oil with surfactant into the microfluidic sorting 
device, respectively. Since drops and oil with surfactant are injected at different rates, only the pump system allows 
such controls in flow rates. The actual flow rates inside the microfluidic channels may be slightly different but 
have not been measured. Similar flow rate settings for drop sorting have been used in previous publications19,31,32.
The microfluidic device for Fluorescence Activated Drop Sorting (FADS) comprises a re-injection inlet that 
introduces drops and an oil inlet that spaces drops. The channels from these inlets intersect at a spacing junction, 
which is followed by a Y-shaped sorting junction connected to a sorting channel and a waste channel. The sort-
ing channel is designed to have a higher fluidic resistance than the waste channel. As a result, all drops flow into 
the waste channel when sorting is not activated. We recorded the drop fluorescence as they passed through the 
detection region onto which a laser was aligned and their fluorescence was focused onto a photomultiplier tube 
(Hamamatsu). A custom computer LabView program running on a real-time field-programmable gate array card 
(National Instruments) digitized the photomultiplier tube signal, as shown in Fig. 1B. All drops were gated based 
on detector pulse width to exclude outliers, such as merged or split drops. When the fluorescence intensity of the 
drop was above a set threshold, the sorting electric field was turned on, resulting in a dielectrophoretic force that 
moved drops toward the sorting channel.
For no template, p53p-DB and PMI-DB, we examined ∼ 100,000 drops. For the PMI library, we examined 
∼1,000,000 drops. For PMI-DB, we isolated five bright drops. To prevent evaporation and facilitate liquid han-
dling for downstream processing of a small number of sorted drops, we preloaded the collection tip with 30 μl of 
carrier drops containing ddH2O. These five bright drops were mixed with 30 μl of carrier drops and distributed 
into 30 wells of a well-plate to ensure separation of individual bright drops. For the PMI library, we collected 13 
bright drops together. As the quality control, we also collect 32,000 dark drops.
RT-PCR amplification of binder templates in sorted drops. We broke the drop emulsion by adding 
20% of 1H,1H,2H,2H-perfluorooctanol (PFO) (Alfa Aesar) followed by vortex and centrifugation. To prepare 
the samples distributed in 30 wells for Sanger sequencing, we added 5 μl of ddH2O to each well in order to facil-
itate transfer of the aqueous phase into 25 μL of the single-step RT-PCR cocktail. This cocktail contained 1 μL 
of OneStep RT-PCR Enzyme Mix with 1 × buffer (Qiagen), 400 μM dNTPs, and 0.25 μM forward and reverse 
primers. To prepare the samples from the PMI library for deep sequencing, we directly transfered the aqueous 
phase into the RT-PCR cocktail. Thermocycling conditions were 50 °C for 30 min, 95 °C for 10 min, 35 cycles of 
95 °C for 30 s, 58 °C for 30 s, and 72 °C for 40 s, followed by 72 °C for 5 min. The PCR products were run on a 2% 
agarose gel and purified using GenElute™ Gel Extraction Kit (Sigma), either sent out for Sanger sequencing or 
processed for Deep sequencing.
Deep Sequencing and data analyses. Illumina-specific adaptor sequences were attached to the 5′ - and 
3′ -ends of the PCR fragments in two consecutive steps of PCR according to the manufacturer’s instructions. The 
sequencing condition was set to a read length of 56 base-pairs that covered the PMI peptide sequence region. 
Sequencing was run on an Illumina Genome Analyzer II (GAII) platform at the sequencing core facility at NEB. 
To analyse the sequencing data, we first removed Illumina adapter sequence and low quality bases (Q < 20) from 
the 3′ end of the raw reads by Cutadapt33. Each read was scanned for constant regions and the random mutated 
codons were extracted based on sequence syntax by custom perl script. The extracted DNA codons were trans-
lated to amino acid sequence using custom perl script. Next the peptide diversity at each mutagenesis position as 
well as the genotype (DNA sequence) diversity corresponding to each phenotype (peptide) was analysed using R 
software34 and listed in Supplementary Table S2.
Results and Discussion
The principle and strategy of the drop-IVT2H screening method. The drop-IVT2H screening 
method (Fig. 1) is based on the IVT2H system developed for the detection of protein-protein interaction in a 
bulk solution20. IVT2H contains a minimal set of components necessary for transcription activation and protein 
translation. IVT2H is designed to express two fusion proteins containing a bait and a prey, respectively. In the 
event of a high-affinity binding between the bait and the prey, the expression of a fluorescence reporter such as 
GFP is activated, resulting a detectable signal. This well-controlled in vitro system avoids the complications asso-
ciated with the classic yeast two-hybrid (Y2H) system, such as efflux pumps, failure in transporting both fusion 
proteins to nucleus35–39, and high false positive rates (estimated to be from 44% to 91%) due to the intracellular 
complexity40. However, unlike other in vitro methods, such as ribosome and mRNA display, there is no mech-
anism in IVT2H to link the genotype (DNA sequence) with the phenotype (binding). Therefore, IVT2H is not 
suitable for screening a random DNA library. High throughput screening of individual binders using IVT2H in 
plate-based assay format would lead to prohibitive costs in the experimental reagents and other consumables.
Drop-based microfluidics have dramatically impacted high throughput screening methods by decreasing the 
assay volume from microliter to picoliter and at the same increasing the assay speed by orders of magnitude. 
For instance, using drop-based microfluidics, one can perform 108 assays in drops in a single day at a cost of a 
few dollars. In stark contrast, even with the state-of-art high-throughput robotic instruments, it would take ∼ 2 
years at a cost of ∼ 15 million dollars to perform the same number of assays in microtiter plates18. To enable the 
IVT2H method for high-throughput screening at reasonable costs, we compartmentalize single DNA molecules 
into picoliter drops with the IVT2H reagents. This not only creates a genotype-phenotype linkage between the 
DNA sequence of a high-affinity binder and its fluorescence signal, but also allows high throughput screening and 
sorting41–43 (Fig. 1). By using drops, the volume for each IVT2H assay decreases from microliter to picoliter and 
thus the cost for each assay decreases by six orders of magnitude. Simultaneously, the effective concentration of a 
single DNA in a picoliter is significantly higher than that in a bulk solution. The lowest concentration for a binder 
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template in bulk IVT2H was previously found to be 2 pM20. The concentration of a single DNA in a picoliter drop 
is equivalent to 1 pM, which turned out to be sufficient for detection. In addition, the on-line compartmentali-
zation procedure is very fast at 4000 drops per second, and highly automatic, which dramatically minimize the 
usage of consumable materials. In spite of these advantages of drop-based microfluidics, single DNA templates 
in drops often produce too few proteins in cell-free systems to be effectively assayed. To date this has only been 
possible for one template encoding a green fluorescent protein44. A current solution is to amplify single DNA 
templates using in-drop PCR, followed by drop-fusion to add reagents for protein synthesis and enzymatic assays. 
However such multi-step procedure significantly complicates the workflow43. By adapting IVT2H to drop-based 
microfluidics, we showed that we were able to perform a one-pot reaction for screening high-affinity binders at 
the single-DNA level.
Detection of a known high-affinity peptide binder at the single-DNA level. To demonstrate the 
detection of a single DNA template in drop-IVT2H, we used a synthetic duodecimal peptide known as PMI as a 
model. Discovered by phage display, PMI binds to MDM2 with high affinity, thereby inhibiting the interaction of 
human p53 and MDM2 protein23. We fused PMI (binder) to the DNA binding domain (DB) to create the binder 
DNA template PMI-DB, and fused MDM2 (binding target) to the activation domain (AD) to create the target 
DNA template AD-MDM2. After expression of the hybrid fusion proteins from these templates, binding of PMI 
to MDM2 recruited AD to the promoter-bound RNA polymerase, thereby activating the reporter GFP expression 
(Fig. 1A inlet). We have previously demonstrate that in bulk IVT2H, PMI (Kd for MDM2 = 3.2 nM) resulted in 
higher fluorescence than the wild-type p53 peptide (p53p, Kd for MDM2 = 46 nM)20, which is consistent with the 
higher affinity of PMI compared to p53p23.
To allow the detection of a binder at the single template level, we Poisson loaded the binder template, p53p-DB 
or PMI-DB DNA, with IVT2H expressing AD-MDM2 in drops. We observed that only PMI-DB DNA tem-
plate showed some bright drops (with noticeably higher fluorescence than that of the majority of drops), while 
p53p-DB DNA template showed drops with a similar low fluorescence as that of no binder template (Fig. 2). In 
the case of PMI-DB, loading at λ = 0.33 generated more bright drops and drops with higher brightness than at 
λ = 0.1, possibly due to the presence of two or more PMI-DB templates in single drops at λ = 0.33 (Fig. 2). To 
examine these drops in a high-throughput and quantitative way, we used our FADS device to measure the fluores-
cence of each drop that passed the laser detector and generated the fluorescence histograms (Fig. 3). Due to the 
Poisson loading, a majority of drops did not contain any binder template, but they exhibited a low level of fluores-
cence, since there was a basal activity of the RNA polymerase in IVT2H. Accordingly, in each set of experiments, 
we used the fluorescence of drops with no binder template to normalize the fluorescence of drops with binder 
Figure 2. Fluorescence images of drops after off-chip incubation. (a) PMI at λ = 0.33 DNA per drop,  
(b) PMI at λ = 0.1 DNA per drop, (c) p53p at λ = 0.1 DNA per drop, and (d) no binder template. Scale bars are 
100 μm.
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templates. The histogram of p53p-DB exhibited a fluorescence distribution with one major peak at the normal-
ized fluorescence of 1.0, which was identical to that of drops with no binder template. The data suggest that at the 
single DNA template level, the low-affinity binding of p53p to MDM2 did not generate detectable increase in drop 
fluorescence. In contrast, the histogram for PMI-DB exhibited a bimodal distribution with a second major peak 
at the normalized fluorescence of ∼ 2.0 (Fig. 3). The data suggest that the high-affinity binding of PMI to MDM2 
resulted in bright drops with increased fluorescence compared to those with no binder template or with p53p-DB.
According to Poisson statistics at λ = 0.1 DNA per drop, 90.5% drops should contain no binder template, 
which corresponds to the first major peak at the fluorescence of 1.0 in the histograms, 9.0% drops should contain 
one binder template, corresponding to the observed second major peak with fluorescence at ∼ 2.0, and 0.5% drops 
should contain two or more binder templates, corresponding to signals with fluorescence > 3.5 (Fig. 3). Setting a 
threshold value of the normalized fluorescence at 1.3, we counted that 4.9% of all sorted drops were bright drops, 
which could contain one or multiple binder templates. The discrepancy between the predicted and measured fre-
quencies of bright drops, 9.5% vs 4.9%, could be due to the uncertainty of determining the absolute concentration 
of the binder DNA template. We verified that our Poisson loading was consistent with Poisson statistics by tripling 
the PMI-DB binder template concentration and observed additional peak signals corresponding to drops with 
two or more binder templates (PMI-DB λ = 0.33, Fig. 3 and Supplementary Figure S2).
To examine if bright drops indeed contained the PMI-DB template, we isolated five bright drops and broke 
the emulsion to retrieve the aqueous phase. In this aqueous solution there were two categories of nucleic acids 
carrying the genotype information, the input DNA template and the transcribed mRNAs. Since we estimated 
hundreds of mRNAs were generated from the single DNA template, amplification from mRNA should be more 
efficient and less biased than from DNA. We therefore performed RT-PCR rather than PCR to amplify a 350 bp 
region of the mRNA encoding PMI-DB. We successfully obtained the 350 bp amplicon from three of the five 
drops (Supplementary Figure S3) and subsequently confirmed their sequences by Sanger sequencing.
Taken together, these results suggest that drop-IVT2H increased the assay sensitivity, making it possible to 
detect the high-affinity binding at the single template level. We established the protocols to isolate bright drops 
and retrieved their sequence information. These experiments provided the basis for using drop-IVT2H to screen 
a random library for sequences that encode high-affinity binders.
Enrichment of a high-affinity binder from a randomized mutant library using drop-IVT2H. The 
previous structural and biochemical studies have indicated that in the PMI sequence (TSFAEYWNLLSP), all 
three underlined residues of the hydrophobic triad, FWL, are most critical for binding to MDM223. Therefore, 
we synthesized the PMI library from oligonucleotides containing NNK codons at these three positions, with 
N representing an equal mixture of A, G, C, and T, and K representing an equal mixture of G and T. This NNK 
library allows to avoid the stop codons UAA and AGA, as well as to reduce the total redundancy of codons and 
consequently screening efforts. The resulting randomized mutant PMI library should contain 8,000 sequences in 
total, with only one FWL (PMI) sequence. We assembled the random PMI library DNA fragment containing a T7 
promoter from synthesized oligonucleotides (Supplementary Figure S1). To construct the full-length PMI library 
for drop-IVT2H, we performed overlapping PCR to add DB and T7 terminator to the random PMI library DNA 
fragment (Supplementary Figure S1).
In the next step, we encapsulated this full-length PMI library in drops with the IVT2H solution that also 
contained the target DNA template AD-MDM2 and the reporter DNA. To ensure the encapsulation of single tem-
plates, we diluted the PMI library DNA until Poisson distribution parameter λ = 0.1 DNA per drop45. We believe 
λ = 0.1 was the optimal condition for screening the PMI library, considering both the single molecule distribu-
tion and the sorting throughput. To screen a random DNA library, it is important that each DNA molecule of the 
library is well separated in drops, that is, one DNA molecule per drop. Multiple DNA molecules per drop would 
create a false positive due to the possibility that more proteins are made. Based on Poisson distribution, at λ = 0.1, 
we need to screen approximately 10 times more drops than the number of DNA molecules of a library, since ∼ 9% 
Figure 3. Histograms of the normalized drop fluorescence of sorted drops containing PMI, p53 or no 
binder template. For PMI, both λ = 0.33 and λ = 0.1 were measured; for p53p, only λ = 0.1 was measured; 
no binder template drops were also measured as a control. The Y-axis (count) is the number of drops that were 
counted. The X-axis is the normalized fluorescence intensity of each drop (F (a.u.)). The fluorescence of drops 
was normalized by the fluorescence of the population peak of drops with no binder template.
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of drops containing one DNA molecule, while 90% of drops are empty and less than 0.5% of drops containing two 
or more DNA molecules. If λ < 0.1 is used, more drops are empty, we need to screen even more drops in order to 
cover the entire library, which limits the size of the DNA library we are currently capable of screening. If λ > 0.1 
is used, there would be significant percentages of drops containing two or more DNA molecules, thus increasing 
the probability of false positives. For instance, at λ = 0.33, 3% of drops contain two DNA molecules.
We generated a total of three million drops from a 25 μl mixture of the IVT2H solution and the PMI library. 
The total number of drops with single PMI templates (NPMI) can be calculated as NPMI = NDrop λ /NLibrary, where 
NDrop is the total number of microfluidics-generated drops and NLibrary is the DNA library size. In the current case, 
NDrop = 3 × 106, NLibrary = 8000, and λ = 0.1. Based on the above formula, there should be 38 PMI drops among 
three million generated drops, that is, 1 PMI drop per 1.2 × 105 drops. If PMI is the only high-affinity binder 
in the random PMI library, we should observe one bright drop in every 1.2 × 105 drops. However, if there are 
high-affinity binders other than PMI in the library, we should see the ratio of bright drops increases by multiplica-
tion. Different from the PMI-DB-only experiments described in the previous section, the random PMI library is 
not expected to have many high-affinity binders, thus the possibility of two high-affinity binders encapsulated in 
the same drop is extremely rare. Therefore, a bright drop is likely to contain just one high-affinity binder template 
and its significantly increased fluorescence is contributed only to this single molecule.
After off-chip incubation of the collected drops, we re-injected ∼1 million drops for detection and sorting 
in the FADS device. We observed 13 bright drops with a similar range of the normalized fluorescence as “pure” 
PMI when encapsulated at λ = 0.1 (Fig. 4). The calculated ratio of these bright drops to total sorted drops is one 
in 1.3 × 105, which is nearly identical to our previous estimate for the PMI drops. This data suggest that PMI was 
the only high-affinity binder in the random library. We cannot exclude the possibility that a low-affinity binder 
was also co-encapsulated in the same drop as PMI even at λ = 0.1. However, it is not possible that every PMI drop 
contained the same low-affinity binder. Therefore, we were still able to distinguish the high-affinity binder from 
the low-affinity one by using the deep sequencing tool. In a separate sorting experiment, we collected 32,000 dark 
drops as a control.
To confirm that the bright drops indeed contained the PMI template, we broke the emulsion of the collected 
bright drops and amplified mRNA via RT-PCR. Though dark drops did not generate significantly increased flu-
orescence, they contain mRNA with similar sequences as bright drops. Therefore, we also amplified mRNA from 
dark drops as a control. The resulting 350 bp DNA fragments from both bright and dark drops along with the ran-
dom library were analysed by deep sequencing. The sequencing data of the input library confirmed that all 8000 
intended sequences were present in the library (Supplementary Table S2), and therefore they were all assayed in 
drop-IVT2H. Based on the deep sequencing data, we plotted the frequencies of three residues that occur at the 
positions of the hydrophobic triad against all 8000 peptide sequences and generated the frequency histograms 
(Fig. 5). The histogram of bright drops indicates that the PMI sequence, FWL, occurred at 21%, which was signif-
icantly higher than other sequences (Fig. 5A, red). In comparison, the frequency of FWL in the histogram of the 
input library was only 0.043% (Fig. 5B, blue). Therefore, the isolation of bright drops by drop-IVT2H resulted in 
a 488-fold enrichment of the PMI sequence. In the control experiment, the frequency of FWL in the histogram 
of dark drops was 0.079% (Fig. 5B, dark red), indicating that there was no significant enrichment of the PMI 
sequence in dark drops.
The frequency histogram of bright drops also reveals a number of other peptide sequences that occurred 
at significant frequencies (Fig. 5A, labelled in three letters). We speculate that these sequences arose from 
in vitro transcription by T7 RNA polymerase as soon as the random library was mixed with the IVT2H reagents 
and before drop encapsulation. These mRNA transcripts were randomly distributed in drops and later amplified 
with varying biases by RT-PCR, which resulted in a wide range of frequencies observed in the deep sequencing 
data for bright drops. To confirm that slightly enriched sequences, such as FSL and FWR, were not high-affinity 
Figure 4. Histograms of the normalized drop fluorescence of sorted drops containing the random PMI 
library, PMI, its variants (FWR and FSL), or no binder template. DNA templates were diluted to λ = 0.1 
DNA per drop. The Y-axis (count) is the number of drops that were counted. The X-axis is the normalized 
fluorescence intensity of each drop (F (a.u.)). The fluorescence of drops was normalized by the fluorescence of 
the population peak of drops with no binder template.
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binders, we constructed individual DNA templates encoding FSL-DB and FWR-DB for drop-IVT2H analysis. 
Histograms of the normalized drop fluorescence show that the fluorescence distributions of FWR and FSL at the 
single-template level (λ = 0.1) were almost identical to that with no template (Fig. 4). Taken together, these results 
show that high-affinity binder templates were significantly enriched in bright drops, and it is feasible to use the 
drop-IVT2H system to sort and isolate high-affinity binder sequences from a random DNA library.
Conclusion
We developed a drop-IVT2H method that enabled robust and high-throughput screening of high-affinity pep-
tide binders at the single DNA template level and without pre-amplification and multistep drop manipulation. 
This mix-and-read drop-based microfluidic platform potentially provides a simple, fast and cost-effective way 
to discover peptide-based drugs, such as anti-microbial46 and anti-thrombotic peptides47 that can either interact 
with specific target proteins, or alter target protein-protein interactions. Unlike the majority of conventional 
antibiotics, antimicrobial peptides may also have the ability to enhance immunity by functioning as immune 
modulators48.
The major advantage of drop-IVT2H is that the expression of the binder and the target is coupled to the 
detection of the binding interaction in a continuous and streamlined drop-based microfluidic workflow. Unlike 
molecular display methods, there are no interruptive steps in drop-IVT2H, such as cell cultures, target immobi-
lization, washing and elution. In fact, what distinguishes drop-IVT2H from all other screening methods is that 
drop-IVT2H does not require target purification and immobilization, and directly detects the binary binding 
interaction in solution rather than on a solid or cell surface (Table S1). Though in this work we demonstrated 
the screening of a peptide binder, drop-IVT2H can also be used to screen protein binders such as single-chain 
antibodies, antibody mimetics or protein ligands. Here a potential limitation is whether IVT2H can produce 
correctly-folded proteins. In vitro systems often have the disadvantage of expressing large and complex pro-
teins due to the lack of appropriate folding environments compared to cell-based systems. Another limitation 
of drop-IVT2H is that it is difficult to screen the binding interaction that involves eukaryotic post-translational 
modifications such as glycosylation, ubiquitination, phosphorylation, etc., since IVT2H is derived from a prokar-
yotic cell. Nevertheless, recent advances in drop-based microfluidics have expanded to encapsulation and analysis 
of single cells in drops49. We have also demonstrated the potential use of a modified IVT2H for single-cell protein 
analysis in drop-based microfluidics31.
In this work, we screened and sorted 106 drops in just half an hour, which was sufficient to assay a library size 
of 105 molecules. With the state-of-art microfluidic techniques, we should be able to increase the library size 
to 106, which may be suitable for screening a target-focused library where a few specific changes are made by 
site-directed mutagenesis50,51. To screen an even larger library that is comparable to other methods (Table S1), 
it may be possible to improve the sorting speed or load multiple DNA templates into each drop, followed by 
successive rounds of screening for further enrichments. Alternatively, drop-IVT2H could be modified to incor-
porate an alternative amplification scheme (10). Instead of activating a fluorescent reporter, drop-IVT2H may 
express a polymerase upon the protein-protein interaction to amplify the high-affinity binder template, which 
is then identified by deep sequencing. In spite of these challenges, drop-IVT2H represents a novel method that 
has far reaching potentials not only for screening high-affinity binders, but also for high throughput studies of 
protein-protein interactions.
Figure 5. Frequency histogram representation of deep sequencing data from collected drops. The relative 
frequencies of peptide sequences from bright drops are shown in red (A). The relative frequencies of peptide 
sequences from dark drops (blue) and input library (dark red) are shown in (B). The PMI and some frequent 
peptide variants are indicated by three-residue sequences, such as FWL, FSL and FWR, corresponding to the 
randomized positions within the peptide sequence. The PMI sequence is FWL.
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